Ivermectin with immunotherapy for metastatic triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older.
- Your cancer is metastatic triple-negative breast cancer confirmed by lab tests (ER/PR very low and HER2 negative).
- Your cancer has gotten worse after 1–2 prior drug treatments for metastatic disease.
- You’re well enough to participate (ECOG 0–1) and expected to live more than 3 months.
- You must have measurable or “evaluable” tumor spots on scans, and you’ve mostly recovered from prior treatment side effects.
- Your blood and organ tests (like white blood cells, platelets, liver, kidneys, and heart function) are within allowed ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
This trial tests a new combination treatment for metastatic triple-negative breast cancer, using radiation to stimulate the immune system, an immunotherapy drug (pembrolizumab), and a medication that targets immune-suppressing cells. The goal is to boost the body's response to immunotherapy, especially in people who have already received immunotherapy but saw limited benefit.
This trial tests a new drug, ivonescimab, combined with standard chemotherapy before surgery for people with high-risk early-stage triple negative breast cancer. The goal is to see if adding this drug improves treatment response.
This trial tests a new combination of two immunotherapy drugs (INBRX-106 and pembrolizumab) given before surgery for people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests if adding ivermectin, a common anti-parasitic drug, to standard immunotherapy (checkpoint inhibitors) can help fight solid tumors. You may be eligible if you are already on immunotherapy for at least 21 days and have a stable or manageable cancer.
Hear when a new Anatomic Stage IV Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.